Prelude Therapeutics Inc (PRLD) Stock Price, Quote & News

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 467 1280

Website: preludetx.com

Address:

175 Innovation Boulevard, Wilmington, United States

Wizzard88 Mar. 20 at 7:01 PM

$PRLD Somebody grab the knife for God sake !!

0 · Reply

Sw1ngb0t Mar. 19 at 8:05 PM

$PRLD I like this stock for a big long position... definitely going to $10 after that mega candle in November. soooo slow though

0 · Reply

Wizzard88 Mar. 18 at 3:48 PM

$PRLD Ridiculous! People selling on good news !

0 · Reply

Wizzard88 Mar. 18 at 3:24 PM

$PRLD Man the shit is cooked today lol

0 · Reply

focafoca99 Mar. 17 at 9:37 PM

$PRLD got a preclinical AACR abstract accepted for PRT13722, its oral KAT6A degrader

1 · Reply

Jaybird827 Mar. 13 at 4:25 PM

$PRLD it will go back up one day. I’m just gonna keep loading up.

0 · Reply

ppl_first Mar. 13 at 3:48 PM

$PRLD The next things that could actually move the stock are Phase 1 start for PRT12396 (blood cancers), IND filing for the KAT6A degrader (mid-2026), or any partnership expansion with Incyte. But none of those are major binary events, which is why the rally didn’t hold.

0 · Reply

Wizzard88 Mar. 13 at 3:17 PM

$PRLD For the love of God someone grab the knife! The shit keeps dripping 🤣🤦

0 · Reply

Wizzard88 Mar. 13 at 2:40 PM

$PRLD All the gains are gone ! Piece of shit!

0 · Reply

Wizzard88 Mar. 13 at 1:54 PM

$PRLD Why this dripping?!!

1 · Reply

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

Mar 10, 2026, 7:01 AM EDT - 11 days ago

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Feb 3, 2026, 9:00 AM EST - 6 weeks ago

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

Dec 6, 2025, 11:00 AM EST - 3 months ago

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

Nov 26, 2025, 11:10 AM EST - 4 months ago

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Nov 12, 2025, 8:31 PM EST - 4 months ago

Prelude Therapeutics Incorporated (PRLD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:01 AM EST - 4 months ago

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 11, 2025, 11:24 PM EST - 4 months ago

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm

Nov 4, 2025, 7:05 AM EST - 4 months ago

Prelude Therapeutics Announces Strategic Business Update

Nov 4, 2025, 7:01 AM EST - 4 months ago

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Nov 3, 2025, 9:01 AM EST - 4 months ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Oct 17, 2025, 7:30 AM EDT - 5 months ago

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Aug 14, 2025, 7:00 AM EDT - 7 months ago

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 2, 2025, 7:30 AM EDT - 10 months ago

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

May 6, 2025, 4:05 PM EDT - 11 months ago

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 7:30 AM EDT - 11 months ago

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Apr 25, 2025, 4:05 PM EDT - 11 months ago

Prelude Announces Presentations at 2025 AACR Annual Meeting

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Mar 5, 2025, 7:30 AM EST - 1 year ago

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

$Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies$

Dec 11, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Nov 27, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Sep 13, 2024, 10:00 AM EDT - 1 year ago

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Aug 12, 2024, 7:01 AM EDT - 1 year ago

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

May 9, 2024, 7:01 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 7, 2024, 7:01 AM EDT - 2 years ago

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 9, 2024, 4:35 PM EDT - 2 years ago

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Mar 5, 2024, 4:45 PM EST - 2 years ago

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Feb 29, 2024, 4:05 PM EST - 2 years ago

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Feb 15, 2024, 4:05 PM EST - 2 years ago

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Dec 11, 2023, 9:34 AM EST - 2 years ago

Prelude Therapeutics Announces $25 Million Private Placement

Nov 1, 2023, 4:10 PM EDT - 2 years ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Aug 29, 2023, 8:30 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

May 31, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 17, 2023, 4:08 PM EDT - 3 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 8, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Apr 27, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Apr 11, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Mar 15, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Feb 9, 2023, 9:05 AM EST - 3 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

Nov 14, 2022, 8:00 AM EST - 3 years ago

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

Aug 9, 2022, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

May 10, 2022, 8:00 AM EDT - 4 years ago

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

Wizzard88 Mar. 20 at 7:01 PM

$PRLD Somebody grab the knife for God sake !!

0 · Reply

Sw1ngb0t Mar. 19 at 8:05 PM

$PRLD I like this stock for a big long position... definitely going to $10 after that mega candle in November. soooo slow though

0 · Reply

Wizzard88 Mar. 18 at 3:48 PM

$PRLD Ridiculous! People selling on good news !

0 · Reply

Wizzard88 Mar. 18 at 3:24 PM

$PRLD Man the shit is cooked today lol

0 · Reply

focafoca99 Mar. 17 at 9:37 PM

$PRLD got a preclinical AACR abstract accepted for PRT13722, its oral KAT6A degrader

1 · Reply

Jaybird827 Mar. 13 at 4:25 PM

$PRLD it will go back up one day. I’m just gonna keep loading up.

0 · Reply

ppl_first Mar. 13 at 3:48 PM

0 · Reply

Wizzard88 Mar. 13 at 3:17 PM

$PRLD For the love of God someone grab the knife! The shit keeps dripping 🤣🤦

0 · Reply

Wizzard88 Mar. 13 at 2:40 PM

$PRLD All the gains are gone ! Piece of shit!

0 · Reply

Wizzard88 Mar. 13 at 1:54 PM

$PRLD Why this dripping?!!

1 · Reply

Dizzier47 Mar. 12 at 9:41 AM

$PRLD extremely interested to see what happens once it reaches 4.05!

1 · Reply

SMART4TRADER Mar. 12 at 7:34 AM

$PRLD

0 · Reply

SuperGreenToday Mar. 12 at 2:53 AM

$PRLD Share Price: $3.84 Contract Selected: Sep 18, 2026 $5 Calls Buy Zone: $0.98 – $1.21 Target Zone: $1.83 – $2.24 Potential Upside: 77% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

LabPsycho Mar. 11 at 2:13 PM

$PRLD @Jaybird827 Nobody will ever be able to make sense of these moves up and down and up since Nov., esp. considering PRLD quietly canning their IMO main product, INCY buying then filing to sell and just an IND filing. Anyone have any other crazier then my wild speculations below to explain the stock price and market cap of this company. Jay - we need photos! Lol

1 · Reply

Jaybird827 Mar. 11 at 1:53 PM

$PRLD I just wonder if Incyte is slowly moving this up to 4.00 So they can get out. 🤔

0 · Reply

Sw1ngb0t Mar. 11 at 12:23 PM

$PRLD $10+ ... slowly obviously

0 · Reply

OfficialStocktwitsUser Mar. 10 at 8:00 PM

$PRLD RSI: 73.62, MACD: 0.2756 Vol: 0.45, MA20: 2.69, MA50: 2.44 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Sw1ngb0t Mar. 10 at 6:39 PM

$PRLD the longest chug ever

0 · Reply

Jaybird827 Mar. 9 at 12:15 AM

$PRLD maybe we will keep going to opposite way that the market keeps going 😆

1 · Reply

elitechrisvp Mar. 5 at 6:46 PM

$PRLD wow...quiet here

0 · Reply

LabPsycho Feb. 27 at 8:05 PM

$PRLD @ppl_first Well, on the other hand, it did go up 50% for no apparent reason in about a week - nobody complained about that....

2 · Reply

Wizzard88 Feb. 27 at 2:39 PM

$PRLD What’s wrong with this ?!!! Why sell off ?!!!

0 · Reply

Market Cap	187.97M
Revenue (ttm)	12.14M
Net Income (ttm)	-99.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-819.60%
Debt to Equity Ratio	0.00

Volume	339,100
Avg Vol	368,246
Day's Range	N/A - N/A
Shares Out	62.87M
Stochastic %K	14%
Beta	0.79
Analysts	Strong Sell
Price Target	$5.17